Repertoire Immune inks deal with Genentech

23 April 2025

Cambridge, USA-based biotech Repertoire Immune Medicines today announced a collaboration and license agreement with Genentech, a subsidiary of Swiss pharma giant Roche (ROG: SIX), to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease.

Repertoire, which was founded in 2019 by Flagship Pioneering, will deploy its DECODE platform, which uniquely maps the immune synapse, to discover novel therapeutic targets. The company pioneering the discovery and development of programmable T cell-targeted immune medicines

“Repertoire’s DECODE platform uniquely maps the entire immune synapse in patients and thereby enables development of transformative T cell-targeted medicines for autoimmune diseases and cancer,” said Torben Straight Nissen, chairman and chief executive of Repertoire and executive partner at Flagship Pioneering.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK